Table 2. Accumulating cardiotoxicity occurrence rate.
| Items | M0 | M3 | M6 | M9 | M12 | M15 |
|---|---|---|---|---|---|---|
| Heart failure | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Acute coronary syndrome | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.4) |
| Life-threatening arrhythmias | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| ΔLVEF ≥ 10% and LVEF < 53% | - | 0 (0.0) | 6 (8.3) | 9 (12.5) | 11 (15.3) | 12 (16.7) |
| Cardiotoxicity | - | 0 (0.0) | 6 (8.3) | 9 (12.5) | 11 (15.3) | 12 (16.7) |
Values are presented as number (%).
M0 = before initiation of adjuvant therapy; M3 = 3 months after initiation of adjuvant therapy; M6 = 6 months after initiation of adjuvant therapy; M9 = 9 months after initiation of adjuvant therapy; M12 = 12 months after initiation of adjuvant therapy; M15 = 15 months after initiation of adjuvant therapy; LVEF = left ventricular ejection fraction; ΔLVEF = absolute decline of LVEF from M0.